← BiotechTV - NewsNew · 12 min
Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1
Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1
<p>CEO Ros Deegan describes the raise and the new investors that it brings into the company, and updates us on the company's pipeline progress.</p>
podlinkr.com/en/biotechtv-news/7235337281134301
For a poster or slide.